<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2958578-A1" country="EP" doc-number="2958578" kind="A1" date="20151230" family-id="47722294" file-reference-id="316322" date-produced="20180825" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="160453622" ucid="EP-2958578-A1"><document-id><country>EP</country><doc-number>2958578</doc-number><kind>A1</kind><date>20151230</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-13704797-A" is-representative="NO"><document-id mxw-id="PAPP193870212" load-source="patent-office" format="original"><country>EP</country><doc-number>13704797.3</doc-number><date>20130219</date><lang>EN</lang></document-id><document-id mxw-id="PAPP193870213" load-source="docdb" format="epo"><country>EP</country><doc-number>13704797</doc-number><kind>A</kind><date>20130219</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC162031646" ucid="EP-2013053233-W" linkage-type="A" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>2013053233</doc-number><kind>W</kind><date>20130219</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL-1988520685" load-source="docdb">A61K  38/08        20060101AFI20140905BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1988525521" load-source="docdb">C07K  14/47        20060101ALI20140905BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1796760998" load-source="docdb" scheme="CPC">A61K  38/168       20130101 LI20170628BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1796760999" load-source="docdb" scheme="CPC">A61K  38/10        20130101 LI20170628BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1796761000" load-source="docdb" scheme="CPC">A61K  38/08        20130101 LI20170628BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1796761001" load-source="docdb" scheme="CPC">A61K  36/48        20130101 LI20170628BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1796761002" load-source="docdb" scheme="CPC">A23L  33/18        20160801 LI20170628BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1796761003" load-source="docdb" scheme="CPC">C07K  14/4703      20130101 LI20170628BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1984699414" load-source="docdb" scheme="CPC">A23Y2220/63        20130101 LA20160107BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1984700703" load-source="docdb" scheme="CPC">A23Y2240/75        20130101 LA20160107BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1984702923" load-source="docdb" scheme="CPC">A61K  38/00        20130101 LA20160107BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1984702970" load-source="docdb" scheme="CPC">C07K  14/415       20130101 FI20160107BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1984704352" load-source="docdb" scheme="CPC">A23V2002/00        20130101 LA20160107BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT165552332" lang="DE" load-source="patent-office">FUNKTIONELLE PEPTIDE FÜR ADIPOSITASERKRANKUNGEN</invention-title><invention-title mxw-id="PT165552333" lang="EN" load-source="patent-office">FUNCTIONAL PEPTIDES FOR OBESITY DISORDERS</invention-title><invention-title mxw-id="PT165552334" lang="FR" load-source="patent-office">PEPTIDES FONCTIONNELS POUR LES TROUBLES DE L'OBÉSITÉ</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR1103311122" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>DANONE SA</last-name><address><country>ES</country></address></addressbook></applicant><applicant mxw-id="PPAR1103330196" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>DANONE, S.A.</last-name></addressbook></applicant><applicant mxw-id="PPAR1101651492" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Danone, S.A.</last-name><iid>100830592</iid><address><street>Buenos Aires 21</street><city>E-08029 Barcelona</city><country>ES</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR1103324906" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>MONTSERRAT CARRERAS AGUSTI</last-name><address><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR1103323915" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>MONTSERRAT CARRERAS, AGUSTI</last-name></addressbook></inventor><inventor mxw-id="PPAR1101643710" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>MONTSERRAT CARRERAS, AGUSTI</last-name><address><street>Avda. Vilamajor, 43</street><city>08450 Llinars del Vallés (Barcelona)</city><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR1103333733" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>ALVAREZ FERNÁNDEZ CRISTINA</last-name><address><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR1103329607" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>ALVAREZ FERNÁNDEZ, Cristina</last-name></addressbook></inventor><inventor mxw-id="PPAR1101642495" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>ALVAREZ FERNÁNDEZ, Cristina</last-name><address><street>C/ Argentina, 43</street><city>08290 Cerdanyola del Vallés (Barcelona)</city><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR1103322694" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>ANDREU COROMINAS MONTSERRAT</last-name><address><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR1103319140" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>ANDREU COROMINAS, MONTSERRAT</last-name></addressbook></inventor><inventor mxw-id="PPAR1101646170" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>ANDREU COROMINAS, MONTSERRAT</last-name><address><street>C/ Querol, 7</street><city>08849 Sant Climent del Llobregat (Barcelona)</city><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR1103344298" load-source="docdb" sequence="4" format="epo"><addressbook><last-name>RAMÓN VIDAL DANIEL</last-name><address><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR1103342574" load-source="docdb" sequence="4" format="intermediate"><addressbook><last-name>RAMÓN VIDAL, Daniel</last-name></addressbook></inventor><inventor mxw-id="PPAR1101648448" load-source="patent-office" sequence="4" format="original"><addressbook><last-name>RAMÓN VIDAL, Daniel</last-name><address><street>C/. Fco. Tomás y Valiente, 2</street><city>46183 La Eliana (Valencia)</city><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR1103311916" load-source="docdb" sequence="5" format="epo"><addressbook><last-name>BATALLER LEIVA ESTHER</last-name><address><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR1103307975" load-source="docdb" sequence="5" format="intermediate"><addressbook><last-name>BATALLER LEIVA, ESTHER</last-name></addressbook></inventor><inventor mxw-id="PPAR1101648306" load-source="patent-office" sequence="5" format="original"><addressbook><last-name>BATALLER LEIVA, ESTHER</last-name><address><street>C/ Ginesta, 1 bloque 1 pta. 10</street><city>46980 Paterna (Valencia)</city><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR1103341919" load-source="docdb" sequence="6" format="epo"><addressbook><last-name>MARTORELL GUEROLA PATRICIA</last-name><address><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR1103343046" load-source="docdb" sequence="6" format="intermediate"><addressbook><last-name>MARTORELL GUEROLA, PATRICIA</last-name></addressbook></inventor><inventor mxw-id="PPAR1101640322" load-source="patent-office" sequence="6" format="original"><addressbook><last-name>MARTORELL GUEROLA, PATRICIA</last-name><address><street>Avda. del Norte, 37 pta. 9</street><city>46220 Picassent (Valencia)</city><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR1103343461" load-source="docdb" sequence="7" format="epo"><addressbook><last-name>GENOVÉS MARTÍNEZ SALVADOR</last-name><address><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR1103321652" load-source="docdb" sequence="7" format="intermediate"><addressbook><last-name>GENOVÉS MARTÍNEZ, Salvador</last-name></addressbook></inventor><inventor mxw-id="PPAR1101640194" load-source="patent-office" sequence="7" format="original"><addressbook><last-name>GENOVÉS MARTÍNEZ, Salvador</last-name><address><street>C/ Xest, 12</street><city>46960 ALDAIA (Valencia)</city><country>ES</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR1101644175" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Carlos Hernando, Borja</last-name><iid>101409919</iid><address><street>GARRIGUES IP, S.L.P. Hermosilla, 3</street><city>28001 Madrid</city><country>ES</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="EP-2013053233-W"><document-id><country>EP</country><doc-number>2013053233</doc-number><kind>W</kind><date>20130219</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2014127798-A1"><document-id><country>WO</country><doc-number>2014127798</doc-number><kind>A1</kind><date>20140828</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS660731442" load-source="docdb">AL</country><country mxw-id="DS660722309" load-source="docdb">AT</country><country mxw-id="DS660721095" load-source="docdb">BE</country><country mxw-id="DS660794178" load-source="docdb">BG</country><country mxw-id="DS660644066" load-source="docdb">CH</country><country mxw-id="DS660721096" load-source="docdb">CY</country><country mxw-id="DS660755145" load-source="docdb">CZ</country><country mxw-id="DS660731456" load-source="docdb">DE</country><country mxw-id="DS660721097" load-source="docdb">DK</country><country mxw-id="DS660721098" load-source="docdb">EE</country><country mxw-id="DS660639239" load-source="docdb">ES</country><country mxw-id="DS660794179" load-source="docdb">FI</country><country mxw-id="DS660794180" load-source="docdb">FR</country><country mxw-id="DS660731457" load-source="docdb">GB</country><country mxw-id="DS660721103" load-source="docdb">GR</country><country mxw-id="DS660731458" load-source="docdb">HR</country><country mxw-id="DS660755146" load-source="docdb">HU</country><country mxw-id="DS660644075" load-source="docdb">IE</country><country mxw-id="DS660721104" load-source="docdb">IS</country><country mxw-id="DS660794181" load-source="docdb">IT</country><country mxw-id="DS660721105" load-source="docdb">LI</country><country mxw-id="DS660794182" load-source="docdb">LT</country><country mxw-id="DS660722310" load-source="docdb">LU</country><country mxw-id="DS660794183" load-source="docdb">LV</country><country mxw-id="DS660794184" load-source="docdb">MC</country><country mxw-id="DS660722315" load-source="docdb">MK</country><country mxw-id="DS660722316" load-source="docdb">MT</country><country mxw-id="DS660722317" load-source="docdb">NL</country><country mxw-id="DS660755151" load-source="docdb">NO</country><country mxw-id="DS660722318" load-source="docdb">PL</country><country mxw-id="DS660721106" load-source="docdb">PT</country><country mxw-id="DS660640773" load-source="docdb">RO</country><country mxw-id="DS660721119" load-source="docdb">RS</country><country mxw-id="DS660722335" load-source="docdb">SE</country><country mxw-id="DS660731468" load-source="docdb">SI</country><country mxw-id="DS660755152" load-source="docdb">SK</country><country mxw-id="DS660755153" load-source="docdb">SM</country><country mxw-id="DS660639240" load-source="docdb">TR</country></ep-contracting-states><ep-extended-states><ep-extended-state-data><country>BA</country></ep-extended-state-data><ep-extended-state-data><country>ME</country></ep-extended-state-data></ep-extended-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><abstract mxw-id="PA139080069" ref-ucid="WO-2014127798-A1" lang="EN" load-source="patent-office"><p num="0000">The present invention concerns certain peptides obtainable by hydrolysis from soy glycinin by the action of supernatant cultures of strains belonging to the genera Lactobacillus or Streptococcus. These peptides, extracts containing them and food products containing them are useful for the treatment and/or prevention of obesity and oxidative stress.</p></abstract><abstract mxw-id="PA139546624" ref-ucid="WO-2014127798-A1" lang="EN" source="national office" load-source="docdb"><p>The present invention concerns certain peptides obtainable by hydrolysis from soy glycinin by the action of supernatant cultures of strains belonging to the genera Lactobacillus or Streptococcus. These peptides, extracts containing them and food products containing them are useful for the treatment and/or prevention of obesity and oxidative stress.</p></abstract><abstract mxw-id="PA139080070" ref-ucid="WO-2014127798-A1" lang="FR" load-source="patent-office"><p num="0000">La présente invention concerne certains peptides qui peuvant être obtenus par hydrolyse de la glycinine de soja grâce à l'action de cultures de surnageants de souches appartenant au genre Lactobacillus ou Streptococcus. Ces peptides, des extraits les contenant, et des produits alimentaires les contenant, sont utiles pour le traitement et/ou la prévention de l'obésité et du stress oxydatif.</p></abstract><abstract mxw-id="PA139546625" ref-ucid="WO-2014127798-A1" lang="FR" source="national office" load-source="docdb"><p>La présente invention concerne certains peptides qui peuvant être obtenus par hydrolyse de la glycinine de soja grâce à l'action de cultures de surnageants de souches appartenant au genre Lactobacillus ou Streptococcus. Ces peptides, des extraits les contenant, et des produits alimentaires les contenant, sont utiles pour le traitement et/ou la prévention de l'obésité et du stress oxydatif.</p></abstract><description mxw-id="PDES78478175" ref-ucid="WO-2014127798-A1" lang="EN" load-source="patent-office"><!-- EPO <DP n="2"/>--><p id="p0001" num="0001"> FUNCTIONAL PEPTIDES FOR OBESITY DISORDERS </p><p id="p0002" num="0002">FIELD OF THE INVENTION </p><p id="p0003" num="0003">The present invention concerns certain peptides obtainable by hydrolysis from soy glycinin by the action of supernatant cultures of strains belonging to the genera Lactobacillus or Streptococcus. </p><p id="p0004" num="0004">These peptides, extracts containing them and food products containing them are useful for the treatment and/or prevention of obesity and oxidative stress. </p><p id="p0005" num="0005">BACKGROUND PRIOR ART Obesity is a serious epidemic in our modern society leading to the development of multiple detrimental pathologies. Obesity related disorders can lead to multiple long- term complications such as type II diabetes, cardiovascular diseases, several types of cancer and many other maladies. It is clear that behavioral modifications in diet and energy expenditure can result in weight loss or be the cause of obesity when energy intake exceeds energy expenditure. Much focus has been given to potential pharmaceutical treatment against obesity, especially new approaches are based on the search of functional compounds able to inhibit the digestion of dietary lipids (Shi Y, Burn P; 2004; Lipid metabolic enzymes: emerging drug targets for the treatment of obesity; Nat. Rev. Drug Discover. 3: 695-710). In the last decades, a great number of enzymes involved in lipid metabolism have been purified and characterized. Lipases that digest fats, both triacylglycerol and phospholipids, are of major interest for obesity. One of the most important lipases is pancreatic lipase (PL) accounting for the hydrolysis of 50-70% of dietary fats (Mukherjee M; 2003; Human digestive and metabolic lipases: a brief review; J. Mol. Catal. Enzym. B 22: 369-376). In the search for antiobesity compounds, PL inhibition has been one of the most widely studied target mechanisms (Birari RB, Bhutani KK; 2007; Pancreatic lipase inhibitors from natural sources: unexplored potential; Drug Discover. Today 12: 879-889). To date, Orlistat, is the only drug accepted in Europe that reduces fat absorption by a peripheral mechanism of action (Lunder M, Bratkovic, 
<!-- EPO <DP n="3"/>-->
 T, Kreft, S and Strukelj, B; 2005; Peptide inhibitor of pancreatic lipase selected by phage display using different elution strategies; Journal of Lipid Research 46: 1512- 1516). </p><p id="p0006" num="0006">Additionally, there are considerable evidences from cell and animal studies suggesting the importance of pancreatic phospholipase A2 (PLA2) in the digestion and absorption of lipids. The phospholipase A2 (PLA2) family catalyzes the hydrolysis of membrane phospholipids, releasing arachidonic acid (AA), docosahexaenoic acid (DHA), and other polyunsaturated fatty acids (PUFAs). The released PUFAs are precursors of a variety of eicosanoids, 20 carbon compounds that include prostaglandins, thromboxanes, leukotrienes, and lipoxins responsable of inflammatory reactions. It has been demonstrated that PLA2 and its downstream products can act as important biological mediators in adipose tissue, activation of PLA2 by several cytokines suggests that this enzyme function as cellular links between inflammatory pathways and lipid metabolism thereby constituting a key target in obesity (Abbott M, Tang T mad Sul H; 2010; The role of phospholipase A2-derived mediators in obesity; Drug Discovery Today: Disease Mechanisms 7:3-4). </p><p id="p0007" num="0007">On the other hand, most of the genes encoding enzymes of lipid metabolism have been cloned and sequenced from different organisms, including humans. Phylogenetic studies have revealed that lipid metabolism is a very well conserved pathway from yeast to humans opening the way to the use of model organisms in the study of antiobesity drugs. In this sense, the nematode Caenorhabditis elegans is a perfect model organism for the study of obesity (Chiang SH, MacDougald OA; 2003; Will fatty worms help cure human obesity; Trends Genet. 19: 523-525). In fact, analysis in C. elegans of fat reducing gene inactivation using interference RNA have identify 305 genes related with reduced body fat and 1 12 genes involved in increased fat storage, many of them with mammalian homologues (Ashrafi K et al.; 2003; Genome- wide RNAi analysis of Caenorhabditis elegans fat regulatory genes; Nature 421 : 268- 272). Also in C. elegans, lipases are key factors in obesity. Recent reports of groups working on lipases of C. elegans indicate that in this organism fat metabolism is an unexpected link between obesity, reproduction and aging (Wang MC et al.; 2008; Fat metabolism links germline stem cells and longevity in C. elegans; Science 232: 957- 960; Xie T; 2008; Burn fat, live longer; Science 232: 865-866). 
<!-- EPO <DP n="4"/>-->
 Natural compounds potentially preventing the development of obesity and related metabolic disorders have been studied. Gargouri and coworkers reported that some soybean proteins have an inhibitory effect on pancreatic lipase (Gragouri et al ; 1984; Studies on the inhibition of pancreatic and microbial lipases by soybean proteins; J Lipid Res., 25: 1214-1221 ). These molecules do not have a direct effect in the enzyme; they modify the lipid emulsions, avoiding the contact between the enzyme and the substrate. In the same way, several authors have explained the presence of basic proteins in some seed with inhibitory properties of lipase activity and later Miyazaki et al., in the patent US 5,41 1 ,956 described some proteins used as inhibitors of lipase in the treatment of obesity (Wang and Huang; 1984; Inhibitors of lipase activities in soybean and other oil seeds; Plant Physiol., 76:929-934; Tani et al ; 1994; Purification and characterization of proteinous inhibitor of lipase from wheat flour ; J Agri Food Chem., 42:2382-2385; Tsujita et al; 1996; Studies of the inhibition of pancreatic and carboxylester lipases by protamine; J Lipid Res., 37: 1481 -1487; Gragouri et al; 1984; Inhibition of pancreatic and microbial lipases by proteins; Biochim. Biophys. Acta., 795:326-331 ). </p><p id="p0008" num="0008">In the same manner, these and other authors proved that the intestinal lipid absorption was reduced by phenolic substances (i.e., chlorogenic acid, (+) catechin, epicatechin, phloridzin, rutin and procyanidins (condensed tannins)) causing an in vitro inhibitory effect on digestive lipases (Wang et al; 2006; Green tea catechins inhibit pancreatic phospholipase A2 and intestinal absorption of lipids in ovariectomized rats; J Nutr Bioch., 17:492-498), Juhel et al (Juhel et al; 2000; Green tea extract (AR25) inhibits lipolysis of triglycerides in gastric and duodenal medium in vitro; J Nutr.Biochem., 1 1 :45-51 ), Sugiyama et al (Sugiyama et al; 2007; Oligomeric Procyanidins in Apple Polyphenol Are Main Active Components for Inhibition of Pancreatic Lipase and Triglyceride Absorption; J Agric Food Chem., 55:4604-4609) and Rahul et al (Rahul et al; 2007; Pancreatic lipase inhibitors from natural sources: unexplored potential "Drug Discovery" today., 12:19-20). </p><p id="p0009" num="0009">However, the study of functional peptides related with obesity, obtained chemically, biotechnologically or by means of enzymatic treatment from proteins, remains an area to explore, although is raising increasing interest. The present invention is focused on functional peptides useful in the treatment of obesity and 
<!-- EPO <DP n="5"/>-->
 oxidative stress obtained from microbial digestion of glycinin by using lactic acid bacteria strains. </p><p id="p0010" num="0010">SUMMARY OF THE INVENTION </p><p id="p0011" num="0011">Accordingly in a first aspect, the invention relates to peptides with PL (pancreatic lipase) and/or PLA2 (pancreatic phospholipase) inhibiting activities obtainable by hydrolysis from soy glycinin. </p><p id="p0012" num="0012"> In a preferred aspect, the invention relates to a peptide having PL (pancreatic lipase) and/or PLA2 (phospholipase A2) inhibiting activity obtained by hydrolysis of soy glycinin with Streptococcus thermophilus CNCM 1-2776 and/or Streptococcus thermophilus CNCM 1-1630 and/or Lactobacillus paracasei subsp paracasei CNCM I- 4270 for use in the treatment or prevention of obesity and/or oxidative stress. </p><p id="p0013" num="0013"> In a second aspect, the invention relates to peptides with PL and/or PLA2 inhibiting activities, selected from the group consisting of: SEQ ID No. 1 : EEEGGSVLSG, SEQ ID No. 2: SDNFEY, SEQ ID No. 3: EEDQPRPDHPPQRP, SEQ ID No. 4: SVIKPPTD, SEQ ID No. 5: QGENEEEDSGAIVTVK, SEQ ID No. 6: QGENEGEDKGAIVT, SEQ ID No. 7: QDEDEDEDEDKPRPSRP, SEQ ID No. 8: DEDEDEDEDKPRPSRP, SEQ ID No. 9: DEDEDEDKPRPSRP, SEQ ID No. 10: DEDEDKPRPSRPSQG, SEQ ID No. 1 1 : GKREQDEDEDEDEDKPRPSRP, SEQ I D No. 12: HQQEEENEGGSILSG, SEQ ID No. 13: QGENEGEDKGAIVTVK, SEQ ID No. 14: SVIKPPTDE, SEQ ID No. 15: IKPPTDE, SEQ ID No. 16: NEGDVLV, SEQ ID No. 17: YNTGDEPWA, SEQ ID No. 18: HGKHEDDEDEDEEEDQPRPDHPPQRP, SEQ ID No. 19: GKHEDDEDEDEEEDQPRPDHPPQRP, SEQ ID No. 20: DDEDEDEEEDQPRPDHPPQRP, SEQ ID No. 21 :</p><p id="p0014" num="0014">HEDDEDEDEEEDQPRPDHPPQRP, and SEQ ID No. 22: SGPLVNP. </p><p id="p0015" num="0015"> In a preferred aspect the peptides are selected from the group consisting of</p><p id="p0016" num="0016">SEQ ID No. V. EEEGGSVLSG, SEQ I D No. 2: SDNFEY, SEQ ID No. 3: EEDQPRPDHPPQRP, SEQ ID No. 4: SVIKPPTD, SEQ ID No. 5: QGENEEEDSGAIVTVK and SEQ ID No. 6: QGENEGEDKGAIVT, which either in isolated form and/or in the form of an extract may be used for the treatment and/or prevention of an obesity disorder as well as against an oxidative stress. 
<!-- EPO <DP n="6"/>-->
 In a third aspect, the invention relates to a food product which comprises at least one of the peptides with PL (pancreatic lipase) and/or PLA2 (pancreatic phospholipase) inhibiting activities, selected from the group consisting of: SEQ ID No. V. EEEGGSVLSG, SEQ ID No. 2: SDNFEY, SEQ ID No. 3: EEDQPRPDHPPQRP, SEQ ID No. 4: SVIKPPTD, SEQ ID No. 5: QGENEEEDSGAIVTVK and SEQ ID No. 6: QGENEGEDKGAIVT, or an extract comprising at least one of the mentioned peptides useful for the treatment and/or prevention of obesity and oxidative stress. </p><p id="p0017" num="0017"> In a fourth aspect, the invention relates to a pharmaceutical composition which comprises at least one of the peptides with PL (pancreatic lipase) and/or PLA2 (pancreatic phospholipase) inhibiting activities, selected from the group consisting of : SEQ ID No. V. EEEGGSVLSG, SEQ I D No. 2: SDNFEY, SEQ ID No. 3: EEDQPRPDHPPQRP, SEQ ID No. 4: SVIKPPTD, SEQ ID No. 5: QGENEEEDSGAIVTVK and SEQ ID No. 6: QGENEGEDKGAIVT, or an extract comprising at least one of the mentioned peptides useful for the treatment and/or prevention of obesity and oxidative stress. </p><p id="p0018" num="0018"> In a further aspect, the invention relates to the use of certain bacteria from the genus Lactobacillus and Streptococcus, in particular, Streptococcus thermophilus CNCM 1-2776, Streptococcus thermophilus CNCM 1-1630 and Lactobacillus paracasei CNCM I-4270, supernatants or cells containing the proteases of the said strains for obtaining the peptides and or extracts containing the peptides with PL (pancreatic lipase) and/or PLA2 (pancreatic phospholipase) inhibiting activities, selected from the group consisting of : SEQ ID No. 1 : EEEGGSVLSG, SEQ I D No. 2: SDNFEY, SEQ ID No. 3: EEDQPRPDHPPQRP, SEQ ID No. 4: SVIKPPTD, SEQ ID No. 5: QGENEEEDSGAIVTVK and SEQ ID No. 6: QGENEGEDKGAIVT. FIGURES </p><p id="p0019" num="0019">Figure 1 represents the effect on C. elegans body fat reduction of peptide extracts obtained from soy glycinin and selected from PLA2 inhibition assay </p><p id="p0020" num="0020"> Figure 2 represents the effect of protection against an acute oxidative stress by different peptide extracts in C. elegans DETAILED DESCRIPTION OF THE INVENTION 
<!-- EPO <DP n="7"/>-->
 The present invention provides different glycinin peptides obtained by hydrolysis with different strains of lactic acid bacteria for use in treatment and/or prevention of obesity disorder and oxidative stress. These peptides are able to in vitro inhibit lypolitic enzymes (PL and PLA2) and reduce fat accumulation and protect against acute oxidative stress in an in vivo model using Caenorhabditis elegans. </p><p id="p0021" num="0021"> In vitro studies were carried out in order to select several strains of lactic acid bacteria able to release peptides from soy glycinin able to inhibit enzymatic activities of relevance in obesity disorders. Peptide extracts were obtained after 72h of hydrolysis of soy glycinin by supernatant cultures of ten different strains belonging to the genera Lactobacillus or Streptococcus. The generated extracts were screened for their capacity to in vitro inhibit PL and PLA2 enzymes. Finally, the selected peptide extracts were then screened for their ability to reduce fat accumulation using an in vivo model of Caenorhabditis elegans, and subsequently the selected peptide extracts were also tested for their ability to protect against an acute oxidative stress using the same animal system. </p><p id="p0022" num="0022"> As a result of this study, it was found that peptide extracts obtained after hydrolysis of glycinin with proteases from supernatant of some strains were able to in vitro inhibit PL and PLA2, and to reduce fat accumulation and protect against oxidative stress using the in vivo model of C. elegans. The antioxidant peptides responsible for the in vitro PL and PLA2 inhibition and fat reduction in vivo were then identified. </p><p id="p0023" num="0023"> Consumption of these specific peptide extracts can be advantageously used in persons suffering obesity or in persons at risk of suffering obesity, such as people with a family history of obesity or people with problems in lipid metabolism. </p><p id="p0024" num="0024">Selection of strains </p><p id="p0025" num="0025"> For the purpose of selecting the most efficient lactic acid bacteria having protease activity against glycinin, different strains of the genera Lactobacillus and Streptococcus were subject to the following hydrolysis assay. </p><p id="p0026" num="0026"> The substrate selected to carry out the process of hydrolysis was soy glycinin. Glycinin is the soy major protein extracted from soy flour after treatment with mercaptoethanol followed by two centrifugation steps as described in Thanh V.H. et al. 
<!-- EPO <DP n="8"/>-->
 (Major proteins of soybean seeds: a straightforward fractionation and their characterization. 1976. J Agric Food Chem 24: 1 1 17-1 121 ). Among the enzymatic sources used to degrade glycinin, ten strains were tested: 6 strains from Streptococcus genera (strains 2, 3, 4, 5, 6, 7) and 4 strains from Lactobacillus genera (strains 8, 9, 10 and 1 1 ). All these strains were grown in optimal medium (MRS for Lactobacillus strains and BHI for Streptococcus strains) during 17h at 37°C and the proteases with a molecular weight above 10 KDa both in supernatant and cells were concentrated to be used as enzymatic sources in glycinin hydrolysis assays. On one hand, proteases from the supernatant were obtained after centrifugation for 15 min at 4000 rpm. Then the supernatant was ultrafiltrated by 10 KDa and the top was resuspended in 2 ml with 50 mM citrate phosphate buffer pH 7. On the other hand, cells obtained from the different cultures were washed with saline solution for 15 min at 4000 rpm and resuspended in 50 mM citrate phosphate buffer pH 7 to evaluate the protease activity in cells and supernatant (Table 1 ). </p><p id="p0027" num="0027">Table 1. Protease activity from different culture collection LAB strains. </p><p id="p0028" num="0028">Protease activity (U.I. /ml) </p><p id="p0029" num="0029">Strains Microorganisms Supernatant cell </p><p id="p0030" num="0030">Streptococcus thermophilus </p><p id="p0031" num="0031"> 2 0,005 0,003 </p><p id="p0032" num="0032"> CNCM I-2965 </p><p id="p0033" num="0033">Streptococcus thermophilus </p><p id="p0034" num="0034"> 3 0,009 0,001 </p><p id="p0035" num="0035"> CNCM I-2785 </p><p id="p0036" num="0036">Streptococcus thermophilus </p><p id="p0037" num="0037"> 4 0,001 0,002 </p><p id="p0038" num="0038"> CNCM I-4269 </p><p id="p0039" num="0039">Streptococcus thermophilus </p><p id="p0040" num="0040"> 5 0,003 0,001 </p><p id="p0041" num="0041"> CNCM 1-321 1 </p><p id="p0042" num="0042">Streptococcus thermophilus </p><p id="p0043" num="0043"> 6 0,006 0,001 </p><p id="p0044" num="0044"> CNCM I-2776 
<!-- EPO <DP n="9"/>-->
 Streptococcus thermophilus </p><p id="p0045" num="0045"> 7 0,003 0,001 </p><p id="p0046" num="0046"> CNCM 1-1630 </p><p id="p0047" num="0047"> Lactobacillus delbrueckii lactis </p><p id="p0048" num="0048"> 8 0,028 0,009 </p><p id="p0049" num="0049"> CNCM I-4280 </p><p id="p0050" num="0050"> Lactobacillus helveticus </p><p id="p0051" num="0051"> 9 0,010 0,012 </p><p id="p0052" num="0052"> CNCM I-4279 </p><p id="p0053" num="0053"> Lactobacillus paracasei </p><p id="p0054" num="0054"> 10 paracasei CNCM I-4270 0,016 0,005 </p><p id="p0055" num="0055">Lactobacillus paracasei </p><p id="p0056" num="0056"> 1 1 paracasei 0,029 0,006 </p><p id="p0057" num="0057"> CNCM 1-1518 </p><p id="p0058" num="0058">From the above it was seen that the culture supernatant of lactic acid bacteria strains were found to be most efficient in providing the highest protease activity and therefore producing functional peptides in obesity. </p><p id="p0059" num="0059"> Obtention of peptide extracts </p><p id="p0060" num="0060"> Enzymatic hydrolysis was carried out for 72h at 37°C with 13.5 ml of 1 % of glycinin in 50 mM citrate phosphate buffer pH 7 and 1.5 ml of each 10 KDa concentrated culture supernatant under study. The reaction was stopped by ultrafiltration with 3 KDa filters and the lower fractions, containing peptides released after hydrolysis were in vitro evaluated for testing their ability to inhibit lipolytic enzymes as PL and PLA2 and studying their in vivo capacity to reduce fat accumulation in a C. elegans model. </p><p id="p0061" num="0061"> Screening of peptide extracts for their capacity to inhibit in vitro PL and PLA2 enzyme activity </p><p id="p0062" num="0062"> Inhibition of PL was determined using 4-methyl umbelliferyl oleate (4MUO) as substrate as described by Sugiyama et al. (Oligomeric procyanidins in apple 
<!-- EPO <DP n="10"/>-->
 polyphenol are main active components for inhibition of pancreatic lipase and triglyceride absorption. J Agric Food Chem (2007); 55: 4604-4609) with some modifications. Aliquots of 25 μΙ of each peptide extract were incubated with 25 μΙ of PL solution (1 mg/ml) and preincubated for 10 minutes at 26°C with stirring of 500 rpm. Reaction was initiated by adding 50 μΙ of 4MUO (0.1 mM) dissolved in Dulbecco<sup>'</sup>s buffer. After incubation at 26°C for 20 minutes with constant stirring (500 rpm) the reaction was stopped by adding 100 μΙ of 0.1 M sodium citrate buffer (pH 4.2). The amount of 4-methyl umbelliferone released by the enzyme was determined by fluorescence. Peptide extracts were used as inhibitors in the enzymatic assay but had to be diluted 1/20 or 1 /50 because of the interference between the fluorescence and the buffer containing the peptides. </p><p id="p0063" num="0063"> Inhibition of PLA2 enzyme was determined by High Performance Liquid Chromatography (HPLC) using 1 ,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) as substrate as described by Singh et al. (A rapid isocratic high-performance liquid chromatography method for determination of cholesterol and 1 ,2-dioleoyl-sn-glycero-3- phosphocholine. Journal of Chromatography (2005); 1073:347-353). Waters 2695 HPLC with Waters 2996 Photodiode detector Array and a C8 column Hypersil BDS (250 x 4.6 mm, 5 uM) were used carrying out an eluent isocratic method formed by a mixture of ammonium phosphate buffer 50 mM pH 2.7:methanol (15:85, v/v). Table 2 contains PL inhibition values by the peptide extracts obtained from soy glycinin. Table 3 contains PLA2 inhibition values by the peptide extracts obtained from soy glycinin. </p><p id="p0064" num="0064">Table 2. Percentage of PL inhibition by peptide extracts from soy glycinin with supernatants and cells from the analyzed strains. </p><p id="p0065" num="0065"> % I nhibition PL - Glycinin Peptides extracts D(1/20) </p><p id="p0066" num="0066"> Glycinin control 72h 2,4 ± 4,6 </p><p id="p0067" num="0067">Strains Supernatants Cells </p><p id="p0068" num="0068">2 - St. thermophilus 3,0 ± 4,5 2,0 ± 4,9 
<!-- EPO <DP n="11"/>-->
 3 - St. thermophilus 4,5 ±5,6 1,5 ±5,4 </p><p id="p0069" num="0069"> 4 - St. thermophilus 0,7 ±3,3 1,6±4,0</p><p id="p0070" num="0070">5 - St. thermophilus 2,4 ± 5,0 1,1 ±2,4</p><p id="p0071" num="0071">6 - St. thermophilus 0,9 ±3,9 3,7 ±3,2</p><p id="p0072" num="0072">7 - St. thermophilus 2,0 ± 5,6 5,7 ± 1,9</p><p id="p0073" num="0073">8 - L. helveticus 1,3±2,7 4,3 ±3,4 </p><p id="p0074" num="0074">9 - L. acidophilus 3,4 ±3,3 2,1 ±3,5</p><p id="p0075" num="0075">10 - L. paracasei </p><p id="p0076" num="0076"> 2,6 ±3,3 3,3 ±3,1 </p><p id="p0077" num="0077"> subsp paracasei </p><p id="p0078" num="0078"> 11 - L. paracasei </p><p id="p0079" num="0079"> 3,1 ± 5,3 4,5 ±6,2 </p><p id="p0080" num="0080"> subsp paracasei </p><p id="p0081" num="0081">Table 3. Percentage of PLA2 inhibition by peptide extracts from soy glycinin with supernatants and cells from the analyzed strains. </p><p id="p0082" num="0082"> % Inhibition PLA2 - Glycinin Peptide extracts </p><p id="p0083" num="0083"> Glycinin control 72h 9,5 ±7,4 </p><p id="p0084" num="0084"> Strains Supernatants Cells</p><p id="p0085" num="0085">2 - St. thermophilus 6,4 ± 3,2 7,4 ± 1,9 </p><p id="p0086" num="0086"> 3 - St. thermophilus 2,8 ±0,7 19,2 ± 1,3</p><p id="p0087" num="0087">4 - St. thermophilus 4,9 ±0,3 8,6 ±2,4 </p><p id="p0088" num="0088"> 5 - St. thermophilus 5,3 ± 1,7 11,0 ±2,9</p><p id="p0089" num="0089">6 - St. thermophilus 17,1 ±2,3 13,0 ±3,9</p><p id="p0090" num="0090">7 - St. thermophilus 21,5 ± 1,7 6,7 ±4,0 </p><p id="p0091" num="0091"> 8 - L. helveticus 7,9 ± 0,5 3,5 ± 1,1 
<!-- EPO <DP n="12"/>-->
 9 - L acidophilus 9,0 ± 2,6 5,7 ± 3,2 </p><p id="p0092" num="0092"> 10 - L. paracasei subsp </p><p id="p0093" num="0093"> 20,9 ± 1 ,6 7,8 ± 1 ,0 paracasei </p><p id="p0094" num="0094"> 1 1 - L. paracasei subsp </p><p id="p0095" num="0095"> 14,0 ± 3,0 3,5 ± 0,9 paracasei </p><p id="p0096" num="0096">The best inhibitory peptide extracts from soy glycinin were selected to be tested in vivo with C. elegans model. These peptide extracts and their assigned codes are summarized in Table 4. </p><p id="p0097" num="0097"> Table 4. Group of the selected peptide extracts for in vivo analysis </p><p id="p0098" num="0098">Samples selected from PLA2 inhibition % PLA2 assay Sample Code inhibition</p><p id="p0099" num="0099">St. thermophilus 3 cells Glycinin 72h M20G 19.2 ± 1.3</p><p id="p0100" num="0100">St. thermophilus 6 supernatant Glycinin 72h M5G 17.1 ± 2.3</p><p id="p0101" num="0101">St. thermophilus 7 supernatant Glycinin 72h M31 G 21 .5 ± 1.7</p><p id="p0102" num="0102">L. paracasei subsp paracasei 10 supernatant </p><p id="p0103" num="0103"> Glycinin 72h M27G 20.9 ± 1.6</p><p id="p0104" num="0104">L. paracasei subsp paracasei 1 1 supernatant </p><p id="p0105" num="0105"> Glycinin 72h M29G 14 ± 3 </p><p id="p0106" num="0106">Screening of peptide extracts for their ability to in vivo reduce fat accumulation </p><p id="p0107" num="0107"> The ability to reduce body fat content in the nematode C. elegans was analyzed in a group of 5 peptide extracts previously obtained from glycinin (see Table 4). These samples were selected by their high effect on PL and PLA2 in vitro inhibition. Specifically, 5 peptide extracts were selected from the PLA2 inhibition assay (M20G, M5G, M31 G, M27G and M29G). Body fat content was analyzed in the C. elegans wild type strain N2 by Red Nile dying of living nematodes. Experiments were carried out with age-synchronized populations, starting from egg-stage to young adult stage (3-day adults). During the experiments, worms were cultured in the NGM agar plates as 
<!-- EPO <DP n="13"/>-->
 control condition, NGM with the corresponding peptide extracts (100 μ-Jplate) and NGM with 6 μg mL of Orlistat as positive control. Nile Red was added on top of the NG plates already seeded with Escherichia coli OP50 strain to a final concentration of 0.05 μg ml. After incubation at 20°C, young adult worms (60 worms per condition) were taken to measure the in vivo fluorescence in a VersaFluorTM Fluorometer System. Fluorescence obtained in treated worms was calculated from fluorescence of worms fed in control conditions (reference sample). Experiments were carried out by duplicate. </p><p id="p0108" num="0108"> The overall results obtained in the evaluation of the 5 peptide extracts showed a higher effect on body fat reduction in the case of those with PLA2 inhibitory capacity (Table 5 and Figure 1 ). </p><p id="p0109" num="0109"> Peptide extracts selected from their PLA2 inhibitory effect were, in general, more effective upon lipid reduction in C. elegans (Table 5). The percentage of fluorescence reduction, as shown in Figure 1 , were from 16.2 to 37.7%. It is important to highlight the effect of M5G, M27G and M31 G with 37.7%, 31.6% and 28.6% of fluorescence reduction respectively. </p><p id="p0110" num="0110"> To summarize, it has been found that a group of peptide extracts with a significant in vitro inhibitory effect on PLA2 have also an important in vivo effect on body fat reduction. </p><p id="p0111" num="0111">Table 5. Percentage of C. elegans body fat reduction produced by peptide extracts selected from the previous enzyme inhibition assay. </p><p id="p0112" num="0112">Samples selected from PLA2 inhibition % Fat reduction assay Sample Code (C. elegans)</p><p id="p0113" num="0113">St. thermophilus 3 cells Glycinin 72h M20G 16.05</p><p id="p0114" num="0114">St. thermophilus 6 supernatant Glycinin 72h M5G 37.71</p><p id="p0115" num="0115">St. thermophilus 7 supernatant Glycinin 72h M31 G 28.57</p><p id="p0116" num="0116">L. paracasei subsp paracasei 10 supernatant </p><p id="p0117" num="0117"> Glycinin 72h M27G 31.61</p><p id="p0118" num="0118">L. paracasei subsp paracasei 1 1 supernatant </p><p id="p0119" num="0119"> Glycinin 72h M29G 16.29 
<!-- EPO <DP n="14"/>-->
 Screening of peptide extracts for their capacity to protect against acute oxidative stress </p><p id="p0120" num="0120"> The protection of the selected 5 peptide extracts against an acute oxidative stress was analyzed in the in vivo model of C. elegans. </p><p id="p0121" num="0121"> Experiments were carried out with age-synchronized populations of C. elegans wild type strain N2. The nematodes were fed from egg stage to 5-day adult stage with the different peptide extracts (100 Up\ate). A control fed condition (NGM) and positive control (vitamin C, 0.1 g/mL) were included. After incubation at 20°C, worms were submitted to an oxidative stress by transferring them to new plates with H<sub>2</sub>0<sub>2</sub> (2 mM). Viability of worm population was determined after 5h of incubation in each culture condition. Experiments were carried out by duplicate. </p><p id="p0122" num="0122"> The 5 selected peptide extracts were analyzed in two different trials. The first one (see Figure 2) included the samples which produced the highest in vitro inhibition of PLA2 (they reduce body fat in vivo between 28.6 and 39.1 %). Samples M5G, M31 G, M27G were obtained from glycinin substrates and all of them showed a high protection against oxidative stress in the nematode. We observed high percentages of survival after oxidative stress (between 53 and 64%) compared with control conditions (39.5%). The results show high protection against oxidative stress and ability to reduce fat content in the nematode for peptide extracts M5G, M31 G y M27G. (Figure 2). </p><p id="p0123" num="0123">In summary, a group of 3 peptide extracts, M5G, M31 G, M27G, obtained from glycinin by hydrolysis with strains St. thermophilus 6, L. paracasei subsp paracasei 10 and St. thermophilus 7, have a high effect on fat reduction and a significant protection against oxidative stress in the in vivo model of C. elegans, demonstrating their beneficial effect on both functionalities (Table 6). </p><p id="p0124" num="0124">Table 6. Protection against oxidative stress of peptide extracts selected from PLA2 assay. 
<!-- EPO <DP n="15"/>-->
 Samples selected from PLA2 % Fat reduction % Survival (C. </p><p id="p0125" num="0125"> Sample Code </p><p id="p0126" num="0126">assay (C. elegans) elegans) </p><p id="p0127" num="0127">St. thermophilus 6 </p><p id="p0128" num="0128"> M5G 37.71 56 supernatant Glycinin 72h </p><p id="p0129" num="0129"> St. thermophilus 7 </p><p id="p0130" num="0130"> M31 G 28.57 53 supernatant Glycinin 72h </p><p id="p0131" num="0131"> L. paracasei subsp paracasei </p><p id="p0132" num="0132"> M27G 31 .61 55.5 10 supernatant Glycinin 72h </p><p id="p0133" num="0133">The following strains were then preferably selected for the purpose of the present invention. </p><p id="p0134" num="0134"> Strain 6: Streptococcus thermophilus CNCM I-2776 </p><p id="p0135" num="0135"> Strain 7: Streptococcus thermophilus CNCM 1-1630 </p><p id="p0136" num="0136"> Strain 10: Lactobacillus paracasei subsp paracasei CNCM I-4270 </p><p id="p0137" num="0137"> The present invention also encompasses the use of above mentioned strains, but also mutants strains or genetically transformed strains derived from any one of the parent strains still having protease activity against glycinin and producing the functional peptides of the present invention. These mutant or genetically transformed strains can be strains wherein one or more endogenous gene(s) of the parent strain has (have) been mutated, for instance to modify some of its metabolic properties. They can also be strains resulting from the genetic transformation of the parent strain by one or more gene/s of interest, for instance in order to give to said strains additional physiological features. </p><p id="p0138" num="0138">Identification of functional peptides with capacity to in vitro inhibit PLA2, reduce fat and protect against oxidative stress in C. elegans model </p><p id="p0139" num="0139"> The 3 peptide extracts able to in vitro inhibit PLA2, reduce fat and protect against oxidative stress in vivo were selected to identify the functional peptide sequence present on them. The identification of functional peptides was carried out with samples, M5G, M27G and M31 G and obtained by nESI-MS/MS. 
<!-- EPO <DP n="16"/>-->
 Table 7 contains the peptides sequences identified from glycinin and the number of occurrences in each evaluated sample. All the peptides showed in Table 7 only were present in samples treated with strains St. thermophilus 6 and 7 and Lactobacillus paracasei subsp paracasei 10, and are not identified in the control samples without hydrolytic treatment. </p><p id="p0140" num="0140">Table 7. Frequency peptide sequences from soy glycinin identified in M5G, M27G and M31 G samples. </p><p id="p0141" num="0141"> Molecular </p><p id="p0142" num="0142"> Sequence weight M5G M27G M31 G</p><p id="p0143" num="0143">V.AVSLI DTN.S 831 ,53 1 </p><p id="p0144" num="0144"> Y. LAGNQEQEFLK.Y 1276,07 </p><p id="p0145" num="0145"> Y. LAGNQEQEFLQ.Y 1276,07 1 </p><p id="p0146" num="0146"> L.AGNQEQEFLK.Y 1 162,99 2 2</p><p id="p0147" num="0147">L.AGNQEQEFLQ.Y 1 162,99 1 </p><p id="p0148" num="0148"> Q.GENEGEDKGAIVT.V 1317,85 1 </p><p id="p0149" num="0149"> Q.GENEEEDSGAIVTVKGG.L 1690,05 1 </p><p id="p0150" num="0150"> N.EGEDKGAIVTVKG.G 1301 ,91 1 </p><p id="p0151" num="0151"> N.EGEDKGAIVTVKGG.L 1358,95 1 </p><p id="p0152" num="0152"> N.EEEDSGAIVTVKGG.L 1389,95 1 </p><p id="p0153" num="0153"> E. EEDSGAIVTVKGG. L 1260,95 1 </p><p id="p0154" num="0154"> E. EDSGAIVTVKGG.L 1 131 ,89 1 </p><p id="p0155" num="0155"> V.TAPAMRKPQQEEDDDDEEEQP.Q 2456,41 1 </p><p id="p0156" num="0156"> V.TAPAMRKPQQEEDDDDEEEQPQ.C 2585,41 1 1</p><p id="p0157" num="0157">E. EEEKGAIVTVK.G 1201 ,93 1 </p><p id="p0158" num="0158"> T.FEEPQQPQ.Q 1001 ,89 1 </p><p id="p0159" num="0159"> T.FEEPQQPQQRGQ.S 1470,95 1 1</p><p id="p0160" num="0160">N.ALEPDHRVES.E 1 151 ,93 1 </p><p id="p0161" num="0161"> R.HFNEGDVL.V 928,7 1 </p><p id="p0162" num="0162"> E. EEEEGGSVLSGFSK.H 1452,97 1 </p><p id="p0163" num="0163"> R.EQDEDEDEDEDKPRPSRPSQGK.R 2585,41 1 1 1 
<!-- EPO <DP n="17"/>-->
 E.QDEDEDEDEDKPRPSRPSQGK.R 2456,41 </p><p id="p0164" num="0164"> E.QDEDEDEDEDKPRPSRPSQGKR.N 2612,53 </p><p id="p0165" num="0165"> D.EDEDEDEDKPRPSRPSQG.K 2084,41 </p><p id="p0166" num="0166"> D.EDEDEDEDKPRPSRPSQGK.R 2213,44 </p><p id="p0167" num="0167"> D.EDEDEDEDKPRPSRPSQGKR.N 2369,53 </p><p id="p0168" num="0168"> E.EDSGAIVTVK.G 1017,91 1</p><p id="p0169" num="0169">V.FDGEL.Q 579,44 3</p><p id="p0170" num="0170">E.GGLIQTW.N 774,02 1</p><p id="p0171" num="0171">D.EDDEDEQIPS.H 1 175,77 1</p><p id="p0172" num="0172">E.DEQIPSHPPRRP.S 1428,37 1</p><p id="p0173" num="0173">K.REQDEDEDEDEDKPRPSRP.S 2341 ,48 2</p><p id="p0174" num="0174">K.REQDEDEDEDEDKPRPSRPS.Q 2428,57 2</p><p id="p0175" num="0175">K.REQDEDEDEDEDKPRPSRPSQGK.R 2741 ,53 2 1</p><p id="p0176" num="0176">R.EQDEDEDEDEDKPRPSRP.S 2185,42 1</p><p id="p0177" num="0177">R.EQDEDEDEDEDKPRPSRPS.Q 2272,48 1</p><p id="p0178" num="0178">R.EQDEDEDEDEDKPRPSRPSQG.K 2457,49 1</p><p id="p0179" num="0179">E.DEDEDEDKPRPSRPSQGK.R 2084,5 1</p><p id="p0180" num="0180">K.HEDDEDEDEEEDQPRPDHPPQRP.S 2810,5 1</p><p id="p0181" num="0181">K.HEDDEDEDEEEDQPRPDHPPQRPS.R 2897,56 1</p><p id="p0182" num="0182">E.DDEDEEEDQPRPDHPPQRP.S 2544,58 1</p><p id="p0183" num="0183">E.DEDEEEDQPRPDHPPQRP.S 2185,42 1</p><p id="p0184" num="0184">E.DEDEEEDQPRPDHPPQRPS.R 2272,42 1</p><p id="p0185" num="0185">D.EDEEEDQPRPDHPPQRP.S 2070,46 1</p><p id="p0186" num="0186">D.EEEDQPRPDHPPQRP.S 1826,1 1 </p><p id="p0187" num="0187"> D.EEEDQPRPDHPPQRPS.R 1913,29 1</p><p id="p0188" num="0188">E.EEDQPRPDHPPQRP.S 1697,2 1</p><p id="p0189" num="0189">E.DQPRPDHPPQRP.S 1439,01 3</p><p id="p0190" num="0190">T.FEEPQQPQQR.G 1284,97 1</p><p id="p0191" num="0191">G.DLIAVP.T 626,51 2</p><p id="p0192" num="0192">K.HQQEEENEGGSIL.S 1469,1 1 1</p><p id="p0193" num="0193">K.NLQGENEGEDKGAIVT.V 1673,19 1</p><p id="p0194" num="0194">K.NLQGENEGEDKGAIVTVK.G 1900,41 2 
<!-- EPO <DP n="18"/>-->
 K.GKQQEEENEGSNIL.S 1573,15 </p><p id="p0195" num="0195"> K.GKQQEEENEGSNILS.G 1661 ,13 </p><p id="p0196" num="0196"> L.QGENEEEDSGAIVTVK.G 1704,17 </p><p id="p0197" num="0197"> K.REQDEDEDED.E 1278,53 </p><p id="p0198" num="0198"> K.REQDEDEDEDEDKPRPSRPSQ.G 2556,64 </p><p id="p0199" num="0199"> K.REQDEDEDEDEDKPRPSRPSQG.K 2613,61 </p><p id="p0200" num="0200"> K.REQDEDEDEDEDKPRPSRPSQGKR.N 2898,01 </p><p id="p0201" num="0201">Hydrolyzates M5G and M27G from strains St. thermophilus 6 and Lactobacillus paracasei subsp paracasei 10 were chosen and further purified by Reverse Phase Cromatography in order to identify the peptides responsible of in vivo fat reduction. Reverse Phase Cromatography fractions were assayed towards C. elegans to study fat reduction and identify peptides present in the positives ones from strains St. thermophilus 6 and L. paracasei subsp paracasei 10. (Table 8). </p><p id="p0202" num="0202">Table 8. Peptide sequences from soy glycinin identified in purified fractions from strains St. thermophilus 6 (M5G) and L. paracasei subsp paracasei 10 (M27G) 
<!-- EPO <DP n="19"/>-->
</p><p id="p0203" num="0203">SEQ ID Molecular Fraction Fraction Fraction</p><p id="p0204" num="0204">Peptide Sequence Protein No. weight(Da) 6 7 6 </p><p id="p0205" num="0205"> strain 6 strain 6 strain 10 </p><p id="p0206" num="0206"> Glycinin</p><p id="p0207" num="0207">QDEDEDEDEDKPRPSRP 2055,88 4 4</p><p id="p0208" num="0208">7 G4</p><p id="p0209" num="0209">8 DEDEDEDEDKPRPSRP 1927,99 1 </p><p id="p0210" num="0210"> 9 DEDEDEDKPRPSRP 1683,73 4 8 </p><p id="p0211" num="0211"> 10 DEDEDKPRPSRPSQG 171 1 ,87 1 </p><p id="p0212" num="0212"> 1 EEEGGSVLSG 1091 ,73 1 </p><p id="p0213" num="0213"> 11 GKREQDEDEDEDEDKPRPSRP 2525,89 8 </p><p id="p0214" num="0214"> Glycinin</p><p id="p0215" num="0215">HQQEEENEGGSILSG 1612,89 1 </p><p id="p0216" num="0216"> 12 G1</p><p id="p0217" num="0217">6 QGENEGEDKGAIVT 1445,89 1 </p><p id="p0218" num="0218"> 13 QGENEGEDKGAIVTVK 1672,91 1 </p><p id="p0219" num="0219"> 4 SVIKPPTD 855,46 1 </p><p id="p0220" num="0220"> 14 SVIKPPTDE 984,52 1 </p><p id="p0221" num="0221"> 15 IKPPTDE 798,49 1 </p><p id="p0222" num="0222"> 2 SDNFEY 773,75 2 </p><p id="p0223" num="0223"> Glycinin</p><p id="p0224" num="0224">QGENEEEDSGAIVTVK 1703,99 2 </p><p id="p0225" num="0225"> 5 G2 </p><p id="p0226" num="0226"> Glycinin</p><p id="p0227" num="0227">NEGDVLV 744,54 2 </p><p id="p0228" num="0228"> 16 G5</p><p id="p0229" num="0229">17 YNTGDEPWA 1063,52 1 </p><p id="p0230" num="0230"> HGKHEDDEDEDEEEDQPRPDHPP 3132,55 </p><p id="p0231" num="0231"> 18 QRP </p><p id="p0232" num="0232"> GKHEDDEDEDEEEDQPRPDHPPQ 2995,3 </p><p id="p0233" num="0233"> 19 RP </p><p id="p0234" num="0234"> 20 DDEDEDEEEDQPRPDHPPQRP 2810,68 1 </p><p id="p0235" num="0235"> 21 HEDDEDEDEEEDQPRPDHPPQRI » 2544,13 </p><p id="p0236" num="0236"> 3 EEDQPRFDHPPQRP 1696,83 1 </p><p id="p0237" num="0237"> 22 SGPLVNP 682,58 1 </p><p id="p0238" num="0238">From these purified fractions, a total of 1 1 peptides were selected to be synthesized and evaluated in vivo in the obesity model of C. elegans (Table 9). All peptides were evaluated at 1 μς/ΓτιΙ. of final concentration. </p><p id="p0239" num="0239">Table 9. Glycinin peptides selected for their in vivo evaluation with C. elegans. 
<!-- EPO <DP n="20"/>-->
 SEQ ID Peptide Sequence Source %Fluorescence No. Code Reduction </p><p id="p0240" num="0240"> C.elegans </p><p id="p0241" num="0241">4 P8a SVIKPPTD Strain 6 44,67 ± 10,5 </p><p id="p0242" num="0242">2 P6a SDNFEY Strain 6 40,90 ± 1 1 ,6 </p><p id="p0243" num="0243">3 P14c EEDQPRPDHPPQRP Strain 6 39,37 ± 7,08 </p><p id="p0244" num="0244">5 P16f QGENEEEDSGAIVTVK Strain 6 38,95 ± 8,7 </p><p id="p0245" num="0245">6 P14b QGENEGEDKGAIVT Strain 6 35,30 ± 6,1 </p><p id="p0246" num="0246">1 P10b EEEGGSVLSG Strain 10 33,48 ± 6,1 </p><p id="p0247" num="0247">11 P21 b GKREQDEDEDEDEDKPRPSRP Strain 10 24,91 ± 7,1 </p><p id="p0248" num="0248">12 P15a HQQEEENEGGSILSG Strain 6 22,82 ± 6,1 </p><p id="p0249" num="0249">8 P16e DEDEDEDEDKPRPSRP Strain 6 21 ,86 ± 4 </p><p id="p0250" num="0250">7 P17c QDEDEDEDEDKPRPSRP Strain 10 18,13 ± 5,57 </p><p id="p0251" num="0251">9 P14d DEDEDEDKPRPSRP Strain 6 6,26 ± 7,6 </p><p id="p0252" num="0252">Among them, peptides with capacity to reduce fat accumulation more than 30% were in vitro evaluated towards pancreatic lipase (PL) and phospholipase A2 (PLA2). In the case of PL, IC50 value was determined (Table 10) and in PLA2 study three different concentrations of each peptide were tested (Table 1 1 ). 
<!-- EPO <DP n="21"/>-->
 Table 10. IC50 value of each peptide in PL enzymatic assay. </p><p id="p0253" num="0253"><img id="imgf000021_0001" he="104" wi="146" file="imgf000021_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0254" num="0254">Table 1 1. Percentage of PLA2 inhibition of each peptide at three different concentrations tested. </p><p id="p0255" num="0255"><img id="imgf000021_0002" he="56" wi="156" file="imgf000021_0002.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0256" num="0256">Identification of the most resistant peptides potentially responsible of fat reduction 
<!-- EPO <DP n="22"/>-->
 An in vitro enzymatic digestion model of an in vivo digestive tract was developed for mimicking the physiological conditions to check and certify that each selected peptide was differently degraded throughout the gastro-intestinal tract by the digestive process. Pepsin, pancreatin and bile concentrations were optimized using a published experimental design (Granado-Lorencio et al (2007). J.Agri. Food. Chem., 55, 6387-6394). </p><p id="p0257" num="0257"> By means of a high-performance liquid chromatography (HPLC), it was observed that the peptides P14c and P16f were completely degraded at the beginning of the intestinal phase, while P8a and P14b were resistant until the end of the process where they finally were degraded (Table 12). </p><p id="p0258" num="0258">Table 12. Percentage of peptides degradation in the in vitro digestion model. </p><p id="p0259" num="0259"> Degradation (%) </p><p id="p0260" num="0260">SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID </p><p id="p0261" num="0261"> No. 2 No. 4 No. 6 No. 3 No. 5 </p><p id="p0262" num="0262">P6a P8a P14b P14c P16f </p><p id="p0263" num="0263">Oral phase 5 min. 23,7 1 ,7 6,0 5,3 -1 ,2 </p><p id="p0264" num="0264">Gastric phase 30 min. 31 ,0 -1 ,3 6,7 4,2 65,8 </p><p id="p0265" num="0265">Gastric phase 120 min. 66,9 -1 ,0 8,7 4,6 95,2 </p><p id="p0266" num="0266">Intestinal phase 15 min. 100 51 ,2 36,7 92,9 100,0 </p><p id="p0267" num="0267">Intestinal phase 30 min. 100 71 ,6 48,9 93,2 100,0 </p><p id="p0268" num="0268">Intestinal phase 60 min. 100 90,7 68,8 95,0 100,0 </p><p id="p0269" num="0269">Intestinal phase 120 min. 100 100,0 100,0 95,5 100,0 
<!-- EPO <DP n="23"/>-->
 The peptides of the present invention can be added to a food matrix either in isolated form or in the form of an extract. The peptides of the present invention can be added to the food matrix either alone or in the form of mixtures. </p><p id="p0270" num="0270"> In a preferred embodiment the peptides may be obtained or manufactured by any method known in the art, including synthesis of the pure peptides and (isolated from) protein fractions generated by hydrolysis or fermentation as described in the present specification. </p><p id="p0271" num="0271"> The peptides of the invention may be present in the food product as per se peptides (e,g from synthesizing the pure peptides) or as part of a protein fraction (e.g hydrolyzed or fermented protein). </p><p id="p0272" num="0272"> In a particular embodiment of the present invention the peptides of the invention may be present in a food product as a result of adding the strains of the present invention in the corresponding food matrices containing soy glycinin. </p><p id="p0273" num="0273"> Preferably this food product is a fermented product. The fermented product can be present in the form of a liquid or present in the form of a dry powder obtained by drying the fermented liquid. </p><p id="p0274" num="0274"> Preferably the fermented product is a fresh and dairy product; more preferably fermented milk and/or fermented soy. Preferably the nutritional compositions are pasteurized and sterilized milks, yogurts and fermented milks, such as: </p><p id="p0275" num="0275"> Dairy products, such as sterilized and/or pasteurized milk, yogurts, fermented milks, milk based desserts. Infant and follow-on formulas and baby foods. Fresh and/or pasteurized cheese. Vegetable products, such as, fruit juice products, syrups and/or fruit essences, marmalade, compote and/or jam. Soybean milk and/or extracts, tiger nuts, cereals, nuts and dried fruits, milk and fermented extracts based on soybean, fruits, nuts and dried fruits and cereals. Infant formulas based on milk, milk products, fruits, cereals, rice, baby foods, etc. Fresh, dried and/or freeze dried food supplements issued directly or through food products and specific preparations for the general population or people with weight problems or obesity. Enriched and/or supplemented water and drinks. In general, staple food and/or functional products which are susceptible to be enriched with functional peptides derived from base product 
<!-- EPO <DP n="24"/>-->
 fermentation, and/or extraction of functional peptides, to be added in food matrices as active ingredients. </p><p id="p0276" num="0276"> The amount of the peptides according to the invention in the food product is preferably at least 0.01 g/kg, more preferably from 0.1 to 10 g/kg, even more preferably from 1 to 7 g/kg and most preferably from 3 to 7 g/kg of said peptides, for example 5 g/kg. Preferably the amount of peptides in these food products is chosen such that the amount of peptide per total amount of serving of the food product is from 0.01 to 1 g, preferably 0.1 to 1 g, more preferably 0.1 to 0.7 g and most preferably 0.2 to 0.5 g. </p><p id="p0277" num="0277">EXAMPLES </p><p id="p0278" num="0278">1. Formulation of a food product with the peptides and fat reduction effect </p><p id="p0279" num="0279"> The objective of the present study was to evaluate the antiobesity effect of the more effective peptides obtained from glycinin after their addition to a food matrix. We selected 5 peptides obtained from hydrolysis of glycinin with strain 6 (P8a, P6a, P14c, P16f, P14b) The peptides from glycinin were added to a soy fermented product (Savia® from Danone) both alone or mixed at final concentration of 1 μg/mL. Nematodes were fed with these products and then total lipids were quantified by Nile Red staining. </p><p id="p0280" num="0280"> Table 13 shows the level of fluorescence reduction in nematodes fed with soy fermented product containing the different glycinin peptides or their combination. Results indicate the in vivo effectiveness of all glycinin peptides when they are added to the soy fermented product. Combination of these 5 peptides in the food matrix also provided a significant reduction of fluorescence. </p><p id="p0281" num="0281">Table 13. Percentages of fluorescence reduction in nematodes fed with Savia® (Danone) containing the selected glycinin peptides, P8a, P6a, P14c, P16f and P14b. 
<!-- EPO <DP n="25"/>-->
 % Fluorescence</p><p id="p0282" num="0282">Condition </p><p id="p0283" num="0283"> Reduction </p><p id="p0284" num="0284">NG-Orlistat 29,5 ±0,1</p><p id="p0285" num="0285">NG-Savia 7,9 ±2,9</p><p id="p0286" num="0286">NG-P8a 41,7 ±4,02</p><p id="p0287" num="0287">NG-Savia+P8a 29,8 ±3,3</p><p id="p0288" num="0288">NG-P6a 36,2 ±4,1</p><p id="p0289" num="0289">NG-Savia+P6a 29,5 ±2,5</p><p id="p0290" num="0290">NG-P14c 33,7 ±5,5</p><p id="p0291" num="0291">NG-Savia+P14c 22,5 ± 1,5</p><p id="p0292" num="0292">NG-P16f 33,9 ± 5,7</p><p id="p0293" num="0293">NG-Savia+P16f 28,82 ± 6,6</p><p id="p0294" num="0294">NG-P14b 30,25 ± 4,2</p><p id="p0295" num="0295">NG-Savia+P14b 27,42 ± 4,07</p><p id="p0296" num="0296">NG-P8a+P6a+P14c+P16f+P14b 28,13 ± 1,5</p><p id="p0297" num="0297">NG-Savia+P8a+P6a+P14c+P16f+P14b 29,2 ± 1,4 
</p></description><claims mxw-id="PCLM70078460" ref-ucid="WO-2014127798-A1" lang="EN" load-source="patent-office"><claim id="clm-0001" num="1"><!-- EPO <DP n="26"/>--><claim-text/><claim-text>CLAIMS </claim-text><claim-text> - A peptide having PL (pancreatic lipase) and/or PLA2 (phospholipase A2) inhibiting activity obtained by hydrolysis of soy glycinin with Streptococcus thermophilus CNCM 1-2776 and/or Streptococcus thermophilus CNCM 1-1630 and/or Lactobacillus paracasei subsp paracasei CNCM I-4270 for use in the treatment or prevention of obesity and/or oxidative stress. </claim-text></claim><claim id="clm-0002" num="2"><claim-text> 2.- A peptide according to claim 1 selected from the group consisting of: </claim-text><claim-text> SEQ ID No.1: EEEGGSVLSG, </claim-text><claim-text> SEQ ID No.2: SDNFEY, </claim-text><claim-text> SEQ ID No.3: EEDQPRPDHPPQRP, </claim-text><claim-text> SEQ ID No.4: SVIKPPTD, </claim-text><claim-text> SEQ ID No.5: QGENEEEDSGAIVTVK, </claim-text><claim-text> SEQ ID No.6: QGENEGEDKGAIVT, </claim-text><claim-text> SEQ ID No.7: QDEDEDEDEDKPRPSRP, </claim-text><claim-text> SEQ ID No.8: DEDEDEDEDKPRPSRP, </claim-text><claim-text> SEQ ID No.9: DEDEDEDKPRPSRP, </claim-text><claim-text> SEQ ID No.10: DEDEDKPRPSRPSQG </claim-text><claim-text> SEQ ID No.11: GKREQDEDEDEDEDKPRPSRP, </claim-text><claim-text> SEQ ID No.12: HQQEEENEGGSILSG, </claim-text><claim-text> SEQ ID No.13: QGENEGEDKGAIVTVK, </claim-text><claim-text> SEQ ID No.14: SVIKPPTDE, </claim-text><claim-text> SEQ ID No.15: IKPPTDE, </claim-text><claim-text> SEQ ID No.16: NEGDVLV, </claim-text><claim-text> SEQ ID No.17: YNTGDEPWA, </claim-text><claim-text> SEQ ID No.18: HGKHEDDEDEDEEEDQPRPDHPPQRP, </claim-text><claim-text> SEQ ID No.19: GKHEDDEDEDEEEDQPRPDHPPQRP, 
<!-- EPO <DP n="27"/>-->
 SEQ I D No. 20: DDEDEDEEEDQPRPDHPPQRP, </claim-text><claim-text> SEQ I D No. 21 : HEDDEDEDEEEDQPRPDHPPQRP, and </claim-text><claim-text> SEQ I D No. 22: SGPLVNP, </claim-text><claim-text> for use in the treatment or prevention of obesity and/or oxidative stress. </claim-text></claim><claim id="clm-0003" num="3"><claim-text>3.- A peptide according to claims 1 or 2, selected from the group consisting of:</claim-text><claim-text>SEQ I D No. 1 : EEEGGSVLSG, </claim-text><claim-text> SEQ I D No. 2: SDNFEY, </claim-text><claim-text> SEQ I D No. 3: EEDQPRPDHPPQRP, </claim-text><claim-text> SEQ I D No. 4: SVI KPPTD, </claim-text><claim-text> SEQ I D No. 5: QGENEEEDSGAIVTVK, and </claim-text><claim-text> SEQ I D No. 6: QGENEGEDKGAIVT, </claim-text><claim-text> for use in the treatment or prevention of obesity and/or oxidative stress. </claim-text></claim><claim id="clm-0004" num="4"><claim-text>4.- Food product suitable for the treatment of obesity and/or oxidative stress comprising one or more peptides according to claims 1 to 3. </claim-text></claim><claim id="clm-0005" num="5"><claim-text> 5. - Food product according to claim 4, wherein the peptides are in the form of an extract. </claim-text></claim><claim id="clm-0006" num="6"><claim-text> 6. - Food product according to claim 4, wherein the peptides are in isolated form. </claim-text></claim><claim id="clm-0007" num="7"><claim-text>7.- Food product according to claims 4 to 6, wherein the amount of said peptide per total amount of serving of the food products is from 0.01 to 1 g. </claim-text></claim><claim id="clm-0008" num="8"><claim-text> 8. - Food product according to claims 4 to 7, comprising at least 0.01 g/kg of said peptides. </claim-text></claim><claim id="clm-0009" num="9"><claim-text> 9. - Use of Streptococcus thermophilus CNCM I-2776 and/or Streptococcus thermophilus CNCM 1-1630 and/or Lactobacillus paracasei subsp paracasei CNCM I-</claim-text><claim-text>4270 in the presence of soy glycinin in a process for the production of peptides and extracts according to preceding claims 1 to 3. 
</claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
